3rd Quarter - Report — NVG, LLC for BIOGEN (2009)

Firm

NVG, LLC

Client

BIOGEN

Income

$50,000

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Biosimilars legislation. Promotong innovation and access to Life-Saving Medicine Act ( H.R. 1427 / S. 726) and Pathway for Biosimilars Act (H.R. 1548).

Lobbyist	Covered position, as disclosed
LISA GERMAN FOSTER	—
ANDREA LARUE	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1548 (111th), H.R. 1427 (111th), S. 726 (111th)

Medical/Disease Research/Clinical Labs MED

Comparative effectiveness research,Omnibus Appropriations Act 2009, P.L. 111-8.

Lobbyist	Covered position, as disclosed
LISA GERMAN FOSTER	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Patent Reform Act of 2009 (H.R.1260, S.515).

Lobbyist	Covered position, as disclosed
ANDREA LARUE	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 515 (111th), H.R. 1260 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.